STAT1 modification improves therapeutic effects of interferons on lung cancer cells
- 2.1k Downloads
Interferons (IFNs) have potent anti-proliferative, pro-apoptotic, and immunomodulatory activities against cancer. However, the clinical utility of IFNs is limited by toxicity and pharmacokinetics making it difficult to achieve sustained therapeutic levels especially in solid tumors.
Signal Transducer and Activator of Transcription 1 (STAT1) or a modified STAT1 (designated STAT1-CC) that is hyper-responsive to IFN were overexpressed in lung cancer SPC-A-1 and H1299 cells using lentiviral vectors. Transduction efficiency was monitored using enhanced green fluorescent protein (EGFP) expression. After transduction, cells were treated with interferon-gamma (IFN-γ) or interferon-beta (IFN-β) and monitored for cell proliferation, migration, and invasiveness using Cell Counting Kit-8 and transwell chamber assays and for apoptosis using Annexin V detection by flow cytometry. In addition, levels of STAT1, STAT1 Tyr-701 phosphorylation (pSTAT1), fibronectin, and β-catenin were determined using western blotting. In the case of IFN-γ stimulation, levels of S100A4, proliferating cell nuclear antigen (PCNA), and c-fos expression were also determined.
We found that expression of STAT1 or STAT1-CC enhanced the effect of IFN-γ and, IFN-β on inhibition of human lung cancer cell proliferation, migration and invasiveness. Moreover, STAT1 and STAT1-CC expression caused increases in pSTAT1 and decreases in fibronectin and β-catenin levels. STAT1-CC showed increased effects compared to STAT1 on IFN-γ induced pSTAT1 and down-regulation of S100A4, PCNA, and c-fos levels.
The results show that STAT1-CC exhibited more strength in improving the antitumor response of IFNs in lung cancer cells. Results from this study suggest that combined treatment of IFNs and STAT1-CC might be a feasible approach for the clinical management of lung cancer in the future.
KeywordsSignal transducer and activator of transcription 1 Interferons Lung cancer Cell proliferation Migration
Ala-656 and Asn-658 sites with double-cysteine alternative in the SH2 domain of STAT1
the Janus activated kinase-signal transducer and activator of transcription
STAT1 Tyr-701 phosphorylation
fetal bovine serum
cell counting kit-8
SDS polyacrylamide gel electrophoresis
proliferating cell nuclear antigen
analysis of variance
enhanced green fluorescent protein
inducible nitric oxide synthase
Lung cancer is a highly malignant disease with a dismal prognosis. For example, 80–85 % of lung cancer cases are categorized as non-small cell lung cancers , and the 5-year overall survival rate of non-small cell lung cancer cases remains at less than 10 % despite improvements in surgery, radiotherapy, and chemotherapy . Thus, novel treatment strategies are needed to improve the outcomes of lung cancer patients.
The use of interferons (IFNs) could be a potential strategy in the treatment of lung cancer . IFNs have been shown to have anti-proliferative, anti-angiogenic, pro-apoptotic, and immunoregulatory effects . Type I IFNs (the IFN-α family and IFN-β) have been used with some success for the treatment of several types of cancer, including hematological malignancies and solid tumors . Type II, IFN-γ, also has antitumor activities in various types of cancer [5, 6]. Unfortunately, although IFNs have impressive potential activities against cancer, the clinical utility of IFNs in the treatment of solid tumors has been limited [3, 5]. The half-life of the intra-tumor concentration was short, thus requiring high doses of IFNs for a therapeutic effect that would result in toxic side effects [3, 5].
The IFN/STAT1 pathway is a typical signaling pathway that mediates crosstalk between tumor cells and components of the host microenvironment [7, 8]. IFN activities rely on signaling through three types of IFN receptors (for type I, II, and III IFNs) and the Janus activated kinase-signal transducer and activator of transcription (JAK-STAT) pathway that includes receptor-associated JAKs and STATs as well as downstream modulators, transcription factors, enhancers, and coactivators. STAT1 is a central mediator for IFN-related intracellular signaling and is considered a tumor suppressor protein related to the IFNs . The role of STAT1 in the IFN-signaling pathway in the context of its antiviral actions has been extensively studied . Previous studies have shown that modified STAT1 (STAT1-CC, the SH2 domain of STAT1 Ala-656 and Asn-658 site with double-cysteine alternative) broadly improves IFN signal transduction in human cells . Compared to wild-type STAT1, STAT1-CC increases the capacity of STAT1 Tyr-701 phosphorylation (pSTAT1), nuclear translocation, DNA binding, recruitment of p300/CBP coactivator, and thus IFN efficacy. Encephalomyocarditis viral replication is inhibited in STAT1-CC-expressing cells, a finding which further extends the benefits of STAT1-CC . Overexpression of STAT1-CC in a IFN-resistant cell line results in IFN-inducible control of viral replication and viral clearance, and increases the anti-viral effect in liver cells that are resistant to IFN as well .
It is still unclear whether using the gain-of-function of STAT1-CC could significantly improve the anti-tumor response of IFNs in lung cancer. To address this issue, our present study examined the outcome with overexpression of STAT1 or STAT1-CC genes in lung cancer cells. Since fibronectin, β-catenin, S100A4, proliferating cell nuclear antigen (PCNA) and c-fos have been reported to be involved in the control of cell growth or metastasis in cancers, we also evaluated the effect of STAT1-CC on the expression of these proteins in lung cancer cells. The results demonstrate that STAT1-CC has strong anti-tumor effects in lung cancer cells in response to IFNs and indicate that combined treatment of IFNs and STAT1-CC could be of potential value for further research in vivo and in an eventual therapeutic approach for treatment of human lung cancer.
Human lung cancer cell lines SPC-A-1 and H1299, and human embryonic kidney 293T cells were obtained from the Type Culture Collection of the Chinese Academy of Sciences, Shanghai, China. SPC-A-1 and H1299 cell lines were maintained in RPMI 1640 supplemented with 10 % fetal bovine serum (FBS) and 100 U/ml penicillin/streptomycin (Invitrogen, Carlsbad, CA). Human embryonic kidney 293T cells were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10 % FBS and 100 U/ml penicillin/streptomycin. Cells were cultured in a humidified 37 °C incubator with 5 % CO2.
Lentiviral vector construction and transduction
Cells were lysed on ice with RIPA buffer (Sigma-Aldrich, St. Louis, MO, USA) containing protease inhibitor cocktail (Sigma-Aldrich). Protein content of the lysates was determined using the Bradford Protein Assay kit (Bio-Rad, Hercules, CA, USA). Equal amounts (40 μg/lane) of protein were separated by 12 % SDS PolyAcrylamide Gel Electrophoresis (SDS-PAGE) and transferred to polyvinylidene fluoride (PVDF) membranes (Millipore, Bedford, MA, USA). The blots were incubated with rabbit anti-PCNA antibody (Ab), rabbit anti-phospho-STAT1 (Tyr701) Ab (Cell Signaling Technology, Beverly, MA, USA), rabbit anti-S100A4 Ab (Abcam, Cambridge, UK), mouse anti-β-actin Ab (Santa Cruz Biotechnology, Santa Cruz, CA, USA), mouse anti-fibronectin Ab mouse anti-β-catenin Ab (Santa Cruz Biotechnology), mouse anti-STAT1 Ab, and mouse anti-c-fos Ab (Abcam). Primary Ab binding was detected with secondary antibody (anti-mouse or anti-rabbit HRP-conjugated IgG secondary antibody) that was detected using enhanced chemiluminescence substrate kit (GE Healthcare, Piscataway, NJ, USA). Quantification was performed with a ChemiDoc TM XRS + scanner and Image Lab Software (Bio Rad, CA, USA). The densities of each sample were normalized to the β-actin.
Cell viability assay
Cells were seeded into 96-well plates at a density of 3 × 103 cells/well. At the following time intervals (24, 48, 72, 96 and 120 h), cell viability was assayed using Cell Counting Kit-8 (CCK-8) assay kit (Dojin Laboratories, Kumamoto, Japan) according to the manufacturer’s instructions. To further examine whether STAT1-CC could better enhance IFN-induced growth inhibition in lung cancer cells, the cells transduced with STAT1, STAT1-CC, and EGFP were treated with IFN-γ or IFN-β and cell viability was measured using the CCK-8 assay. For IFN treatment, 1000 cells were seeded into 96-well plates and allowed to attach overnight. Cells were then treated with various concentrations of IFN-γ or IFN-β (R&D, Minneapolis, MN, USA) at different time intervals. Cell viability was assessed by CCK-8 assay kit.
Cell apoptosis analysis
Cell apoptosis was examined by flow cytometry. Control as well as transduced lung cancer cells were plated into 6-well cell culture plates at a density of 6 × 104 cells/well. After treatment with IFN-γ or IFN-β for 4 days, apoptosis was assessed by flow cytometry using the Annexin V apoptosis detection Kit APC from BD Bioscience (San Jose, CA, USA).
Colony formation assay
Both control and transduced lung cancer cells were seeded into 10-cm culture dishes at a density of 5000 cells/dish and were grown in RPMI 1640 containing 10 % FBS for 14 days to form colonies. The colonies were then stained with Coomassie Blue and imaged accordingly.
Cell migration and invasion assay
The effects of STAT1 and STAT1-CC on migration and invasive ability of lung cancer cells in vitro were examined using transwell assays. Transwell assays were performed in Costar transwell cell culture chamber inserts with an 8 μm pore size, placed in a 24-well cell culture plate (Corning Costar Corporation, Cambridge, MA, USA) . Biological triplicates were performed for each of these assays.
For the cell migration assay, cells (1 × 105) were suspended in serum-free medium and seeded to the upper part of chamber. Complete medium with 10 % FBS was added to the lower chamber as a chemoattractant. After 24 h, the transwell membrane was fixed with 4 % paraformaldehyde, and stained with 0.1 % cresyl violet. Migrated cells were counted under a microscope at 400× magnification. For the cell invasion assay, cells (1 × 105) were suspended in serum-free medium and seeded into the upper compartment of the transwell chamber coated with 10 μl of diluted Matrigel (BD Biosciences). Complete medium with 10 % FBS was added to the lower chamber. After 48 h, cells were fixed, stained, and counted.
Statistical significance was determined using the Student’s t test or analysis of variance (ANOVA). A P value of less than 0.05 is considered significant. Data are expressed as mean ± SEM.
Expression of STAT1 or STAT1-CC significantly inhibits lung cancer cell growth
Expression of STAT1 or STAT1-CC inhibits invasion and migration of lung cancer cells
STAT1-CC enhances IFNs-induced growth inhibition of lung cancer cells
STAT1-CC enhances IFNs-induced lung cancer cell apoptosis
STAT1-CC tyrosine phosphorylation was increased in transduced lung cancer cells
IFN-γ receptor (ifngr1)-deficient or Stat1-deficient mice developed tumors more rapidly compared to wild-type mice for both chemically induced and spontaneously arising tumors . These data demonstrate that STAT1 may function as a tumor suppressor. Some spontaneous human tumors have been reported to be selectively unresponsive to IFN-γ due to impaired STAT1 activation and this suggests that as in mouse models, the IFN-STAT1 dependent tumor surveillance mechanism also engages in humans . Type I and Type II IFNs have been used in the treatment of many types of cancers . However, IFNs have limited clinical utility in solid tumors, largely due to their half-life which makes it difficult to achieve sustained therapeutic concentrations [3, 5]. In order to overcome these limitations, many investigators have attempted to improve the effects of IFNs through modification of IFN signaling . Inhibition of endogenous inhibitors of STAT1 phosphorylation (e.g. SOCS1) or DNA binding (e.g. PIAS1) could be used to modify IFN signaling [11, 17, 18]. STAT1-CC with double-cysteine substitutions in the Src homology 2 (SH2)-homodimerization domain markedly increases responsiveness to both types I and II IFNs . The mechanism for improving IFN efficacy depends on increased capacity for transcriptosome assembly at the promoter of interferon-stimulated genes (ISGs) that is manifested by prolonged STAT1 Tyr-701 phosphorylation, DNA-binding and p300/CBP co-activator recruitment . STAT1-CC was also shown to be able to overcome IFN-γ resistance and induce a hepatitis C virus antiviral response in IFN-α resistant replicon cells .
In this study, STAT1 and STAT1-CC genes were successfully overexpressed in lung cancer cells using the lentivirus-mediated gene transfer system. STAT1 is considered to play a significant role in regulating cell proliferation and apoptosis . Previous studies have shown that STAT1 controls anti-tumorigenic functions by upregulating the expressions of caspases 1, 2, 3, 7, and 8 [20, 21, 22, 23] or inducible nitric oxide synthase (iNOS) , p21  and IRF1/p53 pathway , and downregulating expressions of c-myc , and the BCL2 family . STAT1 also acts as a negative regulator of tumor angiogenesis partially through the induction of CXCL10 . Here, we have examined several factors which have been reported to be involved in cell growth, migration, invasion and apoptosis. Fibronectin has been recognized as an important protein for cancer invasiveness and metastasis [29, 30], and β-catenin has been shown to play an essential role in lung tumorigenesis . The levels of both proteins were decreased in STAT1 and STAT1-CC transduced lung cancer cells, but there was a greater reduction of β-catenin in STAT1-CC cells. STAT1 undergoes multiple types of post-translational modifications, e.g. acetylation and ubiquitination in addition to phosphorylation. Although we have found that more p300/CBP co-activator is recruited to the ISG transcriptional complex in STAT1-CC transduced fibrosarcoma cells , the acetylation level of STAT1-CC remains unclear. Kramer et al., have shown that acetylated Stat1 is able to interact with NF-κB p65, resulting in decreased p65 DNA binding, nuclear localization, and expression of anti-apoptotic NF-κB target genes . Lee et al., reported that NF-κB activates fibronectin gene expression in rat hepatocytes . It will be interesting to look at the acetylation level of STAT1-CC in lung cancer cells. β-catenin has been reported to physically interact with NF-κB to form a complex, resulting in reduced NF-κB DNA binding and target gene expression. Moreover, a strong inverse correlation was found between the expression levels of β-catenin and Fas in colon and breast tumor tissues . We will therefore examine whether Fas level was increased in STAT1-CC cells. S100A4 is associated with increased cell growth and metastatic capacity of lung cancer cells, and, PCNA plays an important role in DNA replication and repair. It has been revealed that PCNA is a potential anticancer target . Both S100A and PCNA expression are suppressed by IFN-γ [36, 37]. c-fos proto-oncogene is described as an immediate early response gene, in which the high expression of c-fos can induce the formation of tumors . Interferon-α-2b downregulates the expression of c-fos, H-ras, c-raf-2, c-kit, c-myc, and c-myb in a hairy cell leukemic line . Expression of S100A4, PCNA and c-fos were reduced in STAT1- and STAT1-CC-expressing lung cancer cells, while PCNA and c-fos were decreased to a greater extent in STAT1-CC cells. STAT1 phosphorylation is higher in STAT1-CC cells both at baseline and with IFN-γ treatment. This indicates that the IFN-STAT1 signaling pathway is more active in this cell line, and might represent a potential molecular mechanism in which STAT1-CC could enhance the antitumor response of IFNs through upregulation of gene expression involved in inhibition of cell growth and metastasis in lung cancer cells. The mechanism for regulation of these genes needs further study.
The delivery of therapeutic genes into lung cancer cells is still a challenging approach in gene therapy. Recently, Powell et al., reviewed methods by which viral vectors can be engineered to enhance target specificity and increase transgene expression . On the other hand, the development of small molecules that are able to enhance IFN signaling would validate a roadmap for next generation drugs for treatment of interferon-sensitive tumors [41, 42].
In conclusion, overexpression of STAT1 or STAT1-CC inhibits human lung cancer cell proliferation, migration and invasion, and enhances the antitumor response of IFNs in vitro. STAT1-CC has stronger IFN induced antitumor activity than STAT1 through enhanced STAT1 phosphorylation in lung cancer cells. Together, these data suggest that combined treatment of IFNs and STAT1-CC may represent a useful therapeutic strategy for the clinical management of human lung cancer, though this approach must be evaluated for the safety and efficacy by clinical trials before any clinical applications.
JC, JZ, ND, ZY, and ZC carried out the study, performed the statistical analysis. YZ, LJ and CC performed the study design and drafted the manuscript. DJ and LD carried out the study. MH and YL participated in the design of the study and helped to draft the manuscript. All the authors participated in the discussion, provided conceptual input. All authors read and approved the final manuscript.
This work was supported by funds received from the National Nature Science Foundation of China (81270131, 81400035) and Wenzhou Municipal Science and Technology Bureau (Y20140052) and the National Institutes of Health (NIH) U19-AI070489.
Compliance with ethical guidelines
Competing interests The authors declare that they have no competing interests.
- 3.Wilderman MJ, Sun J, Jassar AS, Kapoor V, Khan M, Vachani A, et al. Intrapulmonary IFN-beta gene therapy using an adenoviral vector is highly effective in a murine orthotopic model of bronchogenic adenocarcinoma of the lung. Cancer Res. 2005;65(18):8379–87. doi: 10.1158/0008-5472.CAN-05-0920.CrossRefPubMedGoogle Scholar
- 20.Bhanoori M, Yellaturu CR, Ghosh SK, Hassid A, Jennings LK, Rao GN. Thiol alkylation inhibits the mitogenic effects of platelet-derived growth factor and renders it proapoptotic via activation of STATs and p53 and induction of expression of caspase1 and p21(waf1/cip1). Oncogene. 2003;22(1):117–30. doi: 10.1038/sj.onc.1206065.CrossRefPubMedGoogle Scholar
- 29.Han S, Khuri FR, Roman J. Fibronectin stimulates non-small cell lung carcinoma cell growth through activation of Akt/mammalian target of rapamycin/S6 kinase and inactivation of LKB1/AMP-activated protein kinase signal pathways. Cancer Res. 2006;66(1):315–23. doi: 10.1158/0008-5472.CAN-05-2367.CrossRefPubMedGoogle Scholar
- 37.Ma B, Jiang H, Jia J, Di L, Song G, Yu J, et al. Murine bone marrow stromal cells pulsed with homologous tumor-derived exosomes inhibit proliferation of liver cancer cells. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. 2012;14(10):764–73. doi: 10.1007/s12094-012-0860-9.Google Scholar
- 39.Harvey WH, Harb OS, Kosak ST, Sheaffer JC, Lowe LR, Heerema NA. Interferon-alpha-2b downregulation of oncogenes H-ras, c-raf-2, c-kit, c-myc, c-myb and c-fos in ESKOL, a hairy cell leukemic line, results in temporal perturbation of signal transduction cascade. Leuk Res. 1994;18(8):577–85.CrossRefPubMedGoogle Scholar
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.